Literature DB >> 32147748

Spectrum of Genetic Autoinflammatory Diseases Presenting with Cutaneous Symptoms.

Hanna Bonnekoh, Monique Butze, Tilmann Kallinich, Naotomo Kambe, Georgios Kokolakis, Karoline Krause.   

Abstract

Autoinflammatory diseases comprise a group of chronic disabling entities characterized by inflammation without the presence of infectious agents, auto-antibodies or antigen-specific T-cells. Many autoinflammatory diseases are caused by monogenic defects, which lead to disturbed immune signalling with release of proinflammatory mediators. In addition to interleukin-1β and interleukin-18, interferons play a key role in the pathophysiology of these disorders. Patients with autoinflammatory diseases show a broad variety of clinical symptoms, including skin involvement. Wheals, pustules and ulcerative lesions are the most common cutaneous findings observed. Knowledge of the clinical presentation of autoinflammatory diseases is crucial for establishing the diagnosis and guiding appropriate treatment. This review focuses on the dermatological findings in selected autoinflammatory disorders based on their distinct pathomechanisms.

Entities:  

Keywords:  genetics; interferon; interleukin-1; autoinflammatory

Mesh:

Substances:

Year:  2020        PMID: 32147748      PMCID: PMC9128980          DOI: 10.2340/00015555-3427

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  135 in total

1.  High-dose ustekinumab for severe childhood deficiency of interleukin-36 receptor antagonist (DITRA).

Authors:  Nadia Bonekamp; Roberta Caorsi; Joost Frenkel; Marco Gattorno; Gian Maria Viglizzo; Marlies de Graaf; Francesca Minoia; Alice Grossi; Paolo Picco; Isabella Ceccherini
Journal:  Ann Rheum Dis       Date:  2017-09-02       Impact factor: 19.103

2.  Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes.

Authors:  Seth L Masters; Aisling Dunne; Shoba L Subramanian; Rebecca L Hull; Gillian M Tannahill; Fiona A Sharp; Christine Becker; Luigi Franchi; Eiji Yoshihara; Zhe Chen; Niamh Mullooly; Lisa A Mielke; James Harris; Rebecca C Coll; Kingston H G Mills; K Hun Mok; Philip Newsholme; Gabriel Nuñez; Junji Yodoi; Steven E Kahn; Ed C Lavelle; Luke A J O'Neill
Journal:  Nat Immunol       Date:  2010-09-12       Impact factor: 25.606

3.  The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist.

Authors:  Matthew Stenerson; Kevin Dufendach; Ivona Aksentijevich; Jillian Brady; Jared Austin; Ann M Reed
Journal:  Arthritis Rheum       Date:  2011-12

4.  Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris.

Authors:  Dorottya M Berki; Lu Liu; Siew-Eng Choon; A David Burden; Christopher E M Griffiths; Alexander A Navarini; Eugene S Tan; Alan D Irvine; Annamari Ranki; Takeshi Ogo; Gabriela Petrof; Satveer K Mahil; Michael Duckworth; Michael H Allen; Pasquale Vito; Richard C Trembath; John McGrath; Catherine H Smith; Francesca Capon; Jonathan N Barker
Journal:  J Invest Dermatol       Date:  2015-07-23       Impact factor: 8.551

5.  Distinct Cutaneous Manifestations and Cold-Induced Leukocyte Activation Associated With PLCG2 Mutations.

Authors:  Oyinade M Aderibigbe; Debra Long Priel; Chyi-Chia Richard Lee; Michael J Ombrello; Vimal H Prajapati; Marilyn G Liang; Jonathan J Lyons; Douglas B Kuhns; Edward W Cowen; Joshua D Milner
Journal:  JAMA Dermatol       Date:  2015-06       Impact factor: 10.282

6.  An autoinflammatory disease due to homozygous deletion of the IL1RN locus.

Authors:  Sreelatha Reddy; Shuang Jia; Rhonda Geoffrey; Rachel Lorier; Mariko Suchi; Ulrich Broeckel; Martin J Hessner; James Verbsky
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

7.  A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency.

Authors:  Qing Zhou; Geun-Shik Lee; Jillian Brady; Shrimati Datta; Matilda Katan; Afzal Sheikh; Marta S Martins; Tom D Bunney; Brian H Santich; Susan Moir; Douglas B Kuhns; Debra A Long Priel; Amanda Ombrello; Deborah Stone; Michael J Ombrello; Javed Khan; Joshua D Milner; Daniel L Kastner; Ivona Aksentijevich
Journal:  Am J Hum Genet       Date:  2012-09-20       Impact factor: 11.025

8.  NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort.

Authors:  Juan I Aróstegui; Cristina Arnal; Rosa Merino; Consuelo Modesto; María Antonia Carballo; Purificación Moreno; Julia García-Consuegra; Antonio Naranjo; Eduardo Ramos; Pilar de Paz; Josefa Rius; Susana Plaza; Jordi Yagüe
Journal:  Arthritis Rheum       Date:  2007-11

9.  Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin.

Authors:  Karla L Lightfield; Jenny Persson; Sky W Brubaker; Chelsea E Witte; Jakob von Moltke; Eric A Dunipace; Thomas Henry; Yao-Hui Sun; Dragana Cado; William F Dietrich; Denise M Monack; Renée M Tsolis; Russell E Vance
Journal:  Nat Immunol       Date:  2008-08-24       Impact factor: 25.606

10.  A novel mutation in the interleukin-1 receptor antagonist associated with intrauterine disease onset.

Authors:  Ender Altiok; Figen Aksoy; Yıldız Perk; Fulya Taylan; Peter W Kim; Barbaros Ilıkkan; Gülten Turkkani Asal; Raphaela Goldbach-Mansky; Ozden Sanal
Journal:  Clin Immunol       Date:  2012-08-16       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.